Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Non Operating Income (2017 - 2025)

Cardiff Oncology's Non Operating Income history spans 11 years, with the latest figure at -$1000.0 for Q4 2025.

  • For Q4 2025, Non Operating Income fell 100.13% year-over-year to -$1000.0; the TTM value through Dec 2025 reached $5000.0, down 99.7%, while the annual FY2025 figure was $5000.0, 99.84% down from the prior year.
  • Non Operating Income for Q4 2025 was -$1000.0 at Cardiff Oncology, up from -$1.8 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $1.1 million in Q2 2023 and bottomed at -$2.0 million in Q3 2023.
  • The 5-year median for Non Operating Income is $44500.0 (2021), against an average of $159166.7.
  • The largest annual shift saw Non Operating Income soared 13966.67% in 2022 before it tumbled 35620.0% in 2025.
  • A 5-year view of Non Operating Income shows it stood at $84000.0 in 2021, then surged by 882.14% to $825000.0 in 2022, then crashed by 101.58% to -$13000.0 in 2023, then soared by 6138.46% to $785000.0 in 2024, then tumbled by 100.13% to -$1000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Non Operating Income are -$1000.0 (Q4 2025), -$1.8 million (Q3 2025), and $834000.0 (Q2 2025).